Infektionsprophylaxe bei Immunsuppression

Schlüsselwörter

Neutropenie - Immundefizienz - Antibiotikatherapie

Keywords

neutropenia - immune deficiency - antibiotics

• Literatur

• 1 Adamu B, Abdu A, Abba AA et al. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. . Cochrane Database Syst Rev 2014; 3 CD008597
• 2 Boršo D, Löbermann M, Fritzsche C et al. Impfen bei Immundefekten oder medikamentöser Immunsuppression. Dtsch Med Wochenschr 2013; 138: 145-150
• 3 Bumbacea D, Arend SM, Eyuboglu F et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Europ Resp J 2012; 40: 990-1013
• 4 Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014; 91: 56-64
• 5 Chee CB, Sester M, Zhang W et al. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013; 18: 205-216
• 6 Chemaly RF, Ullmann AJ, Stoelben S et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. New Engl J Med 2014; 370: 1781-1789
• 7 Chong Y, Shimoda S, Yakushiji H et al. Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One 2014; 9: e85210
• 8 Esfeh JM, Hanouneh IA, Koval CE et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. Liver Transpl 2014; 20: 544-551
• 9 Gafter-Gvili A, Fraser A, Paul M et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 3 CD004386
• 10 Hasse B, Walker AS, Fehr J et al. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014; 58: 2363-2368
• 11 Horwedel TA, Bowman LJ, Saab G et al. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant. Transpl Infect Dis 2014; 16: 261-269
• 12 Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772
• 13 Katchman E, Marquez M, Bazerbachi F et al. A comparative study of the use of selective digestive decontamination prophylaxis in living-donor liver transplant recipients. Transpl Infect Dis 2014; 16: 539-547
• 14 König C, Kleber M, Reinhardt H et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 2014; 93: 479-484
• 15 Lübbert C, Faucheux S, Becker-Rux D et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013; 42: 565-570
• 16 Manuel O, Kralidis G, Mueller NJ et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402-2410
• 17 McLaughlin JM, Equils O, Somerville KT et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013; 15: 329-343
• 18 Meije Y, Fortún J, Len Ó et al. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 2014; 16: 387-396
• 19 Mitsides N, Greenan K, Green D et al. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology 2014; 19: 157-163
• 20 Neofytos D, Treadway S, Ostrander D et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15: 233-242
• 21 Neumann S, Krause SW, Maschmeyer G et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Ann Hematol 2013; 92: 433-442
• 22 Owers DS, Webster AC, Strippoli GF et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. . Cochrane Database Syst Rev 2013; 2 CD005133
• 23 Pyle RC, Butterfield JH, Volcheck GW et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract 0201; 2 (01) 52-58
• 24 Roman A, Manito N, Campistol JM et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 2014; 28 (02) 84-91
• 25 Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients?. Curr Opin Infect Dis 2013; 26: 317-325
• 26 Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep 2014; 13: 235-244
• 27 Souto A, Maneiro JR, Salgado E et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872-1885
• 28 Tacke D, Buchheidt D, Karthaus M et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 2014; 93 (09) 1449-1456
• 29 Verlinden A, Jansens H, Goossens H et al. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol 2014; 93: 302-308
• 30 Wald A, Corey L, Timmler B et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. New Engl J Med 2014; 370: 201-210